top of page

FDA Accepts New Drug Application for Ceftobiprole

Basilea Pharmaceutica has announced that the US FDA has accepted its New Drug Application (NDA) for ceftobiprole. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of 3 April 2024, meaning that Basilea will have a regulatory decision for its lead antibiotic asset in the US in early-Q224, consistent with prior guidance. Supported by three separate Phase III clinical trials, the company is seeking approval for three indications: Staphylococcus aureus bacteraemia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). With the bacterial infection market in the US representing a sizeable opportunity, Edison Group believes the decision from the FDA could represent a significant catalyst for Basilea.



02e30a601a912ddcc2b4a554b198968b
.pdf
Download PDF • 252KB


2 views0 comments

Recent Posts

See All

Comments


bottom of page